Elisrasib

Elisrasib
Clinical data
Other names	D3S-001
Identifiers
	IUPAC name [(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile;
PubChem CID	167251905;
UNII	PFW9YLB86H;
KEGG	D13352;
ChEMBL	ChEMBL5314913;
Chemical and physical data
Formula	C32H35F6N7O3
Molar mass	679.668 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C(=C1C(F)(F)F)[C@@H]2CC3=C(CO2)C(=NC(=N3)OC[C@@]45CCCN4C[C@@H](C5)F)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F)F)N;
	InChI InChI=InChI=1S/C32H35F6N7O3/c1-17-10-22(40)27(35)25(26(17)32(36,37)38)24-11-23-21(15-47-24)28(43-8-9-45(29(46)18(2)33)20(14-43)4-6-39)42-30(41-23)48-16-31-5-3-7-44(31)13-19(34)12-31/h10,19-20,24H,2-5,7-9,11-16,40H2,1H3/t19-,20+,24+,31+/m1/s1; Key:JOLORSRKBHXPFT-PNGHJTAWSA-N;

Elisrasib is an investigational new drug that is being developed by D3 Bio for the treatment of solid tumors. It is a G12C mutant selective KRAS inhibitor.^[1]^[2]^[3]^[4]

References

↑ "Elisrasib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Zhang J, Lim SM, Yu MR, Chen C, Wang J, Wang W, et al. (September 2024). "D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities". Cancer Discovery. 14 (9): 1675–1698. doi:10.1158/2159-8290.CD-24-0006. PMC 11372373. PMID 38717075.
↑ Killock D (July 2025). "Next-generation KRAS-G12C inhibitor D3S-001 shows promise". Nature Reviews. Clinical Oncology. 22 (7): 459. doi:10.1038/s41571-025-01028-8. PMID 40346420.
↑ "Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC". Cancer Discovery. 16 (6): OF1. June 2026. doi:10.1158/2159-8290.CD-NW2026-0041. PMID 42010749.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.